Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway

PurposeTo study composition and heterogeneity of insoluble subvisible particles in Mab formulations resulting from degradation of polysorbate 20 and to develop a better understanding of the mechanisms of polysorbate degradation leading to particle formation.MethodsIn this study, we exploit the potential of Raman microscopy for chemical identification of particles in monoclonal antibody formulations. Through a combination of experiments and density functional theory (DFT) calculations, we identified unique spectral marker bands for insoluble degradation products of polysorbate 20. We first applied our methodology to identify particles in model systems containing complex mixtures of fatty acids and then to subvisible particles in antibody formulations stored at 5°C for several years.ResultsMost of the subvisible particles identified were comprised of mixtures of fatty acids with no observable signal from fatty acid esters consistent with hydrolysis being the predominant degradation mechanism leading to particulate formation under these storage conditions.ConclusionsOur methodology is generally applicable for identification of particles in antibody formulations and, in particular, has the potential to give detailed information about particle heterogeneity and insight into mechanistic aspects of particle formation.

[1]  Parr,et al.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.

[2]  A. Becke Density-functional thermochemistry. , 1996 .

[3]  R. C. Weast CRC Handbook of Chemistry and Physics , 1973 .

[4]  Steven Kozlowski,et al.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.

[5]  Zai-Qing Wen,et al.  Free fatty acid particles in protein formulations, part 1: microspectroscopic identification. , 2015, Journal of pharmaceutical sciences.

[6]  Hanns-Christian Mahler,et al.  The Degradation of Polysorbates 20 and 80 and its Potential Impact on the Stability of Biotherapeutics , 2011, Pharmaceutical Research.

[7]  A. Barth,et al.  What vibrations tell about proteins , 2002, Quarterly Reviews of Biophysics.

[8]  S. Singh,et al.  An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.

[9]  B. Kerwin Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. , 2008, Journal of pharmaceutical sciences.

[10]  H. Yoshida,et al.  A NEW APPROACH TO VIBRATIONAL ANALYSIS OF LARGE MOLECULES BY DENSITY FUNCTIONAL THEORY: WAVENUMBER-LINEAR SCALING METHOD , 2002 .

[11]  S. Shire,et al.  Characterization of Particles in Protein Solutions: Reaching the Limits of Current Technologies , 2010, The AAPS Journal.

[12]  L. Radom,et al.  An evaluation of harmonic vibrational frequency scale factors. , 2007, The journal of physical chemistry. A.

[13]  A. Becke Density-functional thermochemistry. III. The role of exact exchange , 1993 .

[14]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[15]  Vasco Filipe,et al.  Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates , 2010, Pharmaceutical Research.

[16]  Y. Kao,et al.  Quantitation of polysorbate 20 in protein solutions using mixed-mode chromatography and evaporative light scattering detection. , 2008, Journal of chromatography. A.

[17]  Ryszard Pyrz,et al.  Estimation of crystallinity of isotactic polypropylene using raman spectroscopy , 2002 .

[18]  Doris W Lau,et al.  Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator. , 2012, Analytical chemistry.

[19]  W. M. Haynes CRC Handbook of Chemistry and Physics , 1990 .

[20]  Siegfried Wartewig,et al.  Pharmaceutical applications of Mid-IR and Raman spectroscopy. , 2005, Advanced drug delivery reviews.

[21]  S. Boxer,et al.  Measuring electrostatic fields in both hydrogen-bonding and non-hydrogen-bonding environments using carbonyl vibrational probes. , 2013, Journal of the American Chemical Society.

[22]  Wim Jiskoot,et al.  Particles in therapeutic protein formulations, Part 1: overview of analytical methods. , 2012, Journal of pharmaceutical sciences.

[23]  D. Volkin,et al.  Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[24]  Fred Jacobson,et al.  Protein aggregation and bioprocessing , 2006, The AAPS Journal.

[25]  P. Vandenabeele,et al.  Reference database of Raman spectra of biological molecules , 2007 .

[26]  Andreas Neyer,et al.  Raman, mid-infrared, near-infrared and ultraviolet–visible spectroscopy of PDMS silicone rubber for characterization of polymer optical waveguide materials , 2010 .

[27]  J. Yano,et al.  Diversity in the fatty-acid conformation and chain packing of cis-unsaturated lipids. , 1998, Current opinion in structural biology.

[28]  L. Narhi,et al.  A critical review of analytical methods for subvisible and visible particles. , 2009, Current pharmaceutical biotechnology.

[29]  A. Svendsen,et al.  Lipase protein engineering. , 2000, Biochimica et biophysica acta.

[30]  Guntram Rauhut,et al.  Transferable Scaling Factors for Density Functional Derived Vibrational Force Fields , 1995 .